Key result
Dexmedetomidine significantly attenuated the inflammatory response, lowering IL-6 and INF-ɤ levels during and after cardiopulmonary bypass compared to normal saline.
Why the study?
Cardiopulmonary bypass triggers an inflammatory response affecting multiple organs, and the effect of dexmedetomidine on inflammatory markers during pediatric open-heart surgery required evaluation.
Does dexmedetomidine reduce the inflammatory response in children aged 1 to 8 years undergoing elective repair of non-cyanotic congenital heart disease with CPB?
RCT (n=61)
randomly assigned
Does dexmedetomidine reduce the inflammatory response in children aged 1 to 8 years undergoing elective repair of non-cyanotic congenital heart disease with CPB?
Dexmedetomidine significantly attenuates the inflammatory response and reduces the need for inotropic support and mechanical ventilation in children undergoing repair of non-cyanotic congenital heart disease.
Answers are grounded in this paper and cite their sources.
Dexmedetomidine attenuates inflammation during pediatric non-cyanotic CHD repair with CPB; extends RCT evidence to this population.
Background: The inflammatory response due to cardiopulmonary bypass (CBP) activates different inflammatory pathways that affect multiple organs. Dexmedetomidine is proved to affect inflammatory marker production.Objectives: Evaluation of the effect of Dexmedetomidine on the inflammatory response associated with pediatric open-heart surgery using interleukin-6 (IL-6) and interferon-gamma (INF-ɤ) levels.Methods: 61children aged between one to 8 years undergoing elective repair of non-cyanotic congenital heart disease with CPB were randomly assigned into two groups. The control group (31 patients) received normal saline, whereas the Dex group (30 patients) received an initial bolus of Dexmedetomidine 0.5 µg/kg followed immediately by infusion of 0.5 µg/kg/hr continued till the end of CPB. The level of IL-6 and INF-ɤ was measured. Hemodynamic, ICU, and hospital data were recorded.Results: IL-6 and INF -ɤ levels were increased significantly with time in control group, with no increase in their levels in the Dex group. They were significantly lower in the Dex group compared to the control group in samples taken during bypass, 6 h and 24 h after the operation (the end of surgical procedure). There was a significant difference between the groups regarding inotropic score and mechanical ventilation. There was no significant difference between the groups regarding complications, duration of ICU or hospital stay.Conclusion: The use of Dexmedetomidine in pediatric cardiac surgery for non-cyanotic heart disease had significantly attenuated the inflammatory response. It was useful in decreasing the level of inflammatory mediators, inotropic support, and duration of mechanical ventilation, but not the ICU or hospital stay.Trial registration: https://clinicaltrials.gov. (Identifier: NCT03163238).
No takes yet. Share an insight, caveat, or question.
Abdelrahman et al. (2020) conducted an RCT in non-cyanotic congenital heart disease (n=61). Dexmedetomidine vs. normal saline was evaluated on interleukin-6 (IL-6) and interferon-gamma (INF-ɤ) levels. Dexmedetomidine significantly attenuated the inflammatory response, lowering IL-6 and INF-ɤ levels during and after cardiopulmonary bypass compared to normal saline.
Synapse has enriched 10 related papers. Consider them for comparative context: